Mechano-energetic efficiency in patients with hypertrophic cardiomyopathy with and without sarcomeric mutations

J Cardiovasc Transl Res. 2024 Apr;17(2):458-466. doi: 10.1007/s12265-023-10441-2. Epub 2023 Oct 13.

Abstract

Hypertrophic cardiomyopathy (HCM) is mainly caused by sarcomeric mutations which may affect myocardial mechano-energetic efficiency (MEE). We investigated the effects of sarcomeric mutations on MEE. A non-invasive pressure/volume (P/V) analysis was performed. We included 49 genetically screened HCM patients. MEEi was calculated as the ratio between stroke volume and heart rate normalized by LV mass. Fifty-seven percent (57%) HCM patients carried a sarcomeric mutation. Patients with and without sarcomeric mutations had similar LV ejection fraction, heart rate, LV mass, and LV outflow gradient. Younger age at diagnosis, family history of HCM, and lower MEEi were associated with presence of sarcomeric mutation (p = 0.017; p = 0.001 and p = 0.0001, respectively). Lower MEEi in HCM with sarcomeric mutation is not related to significant differences on filling pressure as shown on P/V analysis. Sarcomeric mutations determine a reduction of the LV pump performance as estimated by MEEi in HCM. Lower MEEi may predict a positive genetic analysis.

Keywords: Hypertrophic cardiomyopathy; Mechano-energetic; Non-sarcomeric HCM; Sarcomeric HCM.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Cardiomyopathy, Hypertrophic* / genetics
  • Cardiomyopathy, Hypertrophic* / physiopathology
  • DNA Mutational Analysis
  • Female
  • Genetic Predisposition to Disease*
  • Heart Rate*
  • Humans
  • Male
  • Middle Aged
  • Mutation*
  • Myocardial Contraction
  • Phenotype*
  • Sarcomeres* / genetics
  • Sarcomeres* / metabolism
  • Stroke Volume*
  • Ventricular Function, Left*
  • Ventricular Pressure
  • Young Adult